Tagged for success? Singapore start-up BioLynx hits the ground running
This article was originally published in Scrip
A new bioventure spun off from research at the National University of Singapore is aiming to apply its tagging technology to a broad range of drugs to improve understanding of how they work at the cellular level, and is already set to launch its first product over the next few months.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.